Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition

This article was originally published in The Gray Sheet

Executive Summary

Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.

Advertisement

Related Content

Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date
EuroPCR in Brief
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
St. Jude Plans Trial To Study Renal Denervation Outcomes
St. Jude Plans Trial To Study Renal Denervation Outcomes
The Renal Denervation Buzz: Separating Fact From Myth
New Products In Brief
With Trial Approval, Medtronic Aims For Symplicity RF Catheter Launch In 2014
Medtronic Bets On Blockbuster Hypertension Market With Ardian Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT031718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel